US company backs out of Elan deal
A US company today backed out of a €785m deal to buy the primary care business unit and two brand-name drugs from the Elan Corporation.
King Pharmaceuticals of Tennessee claimed in a statement that Elan committed “various breaches and misrepresentations” involving the asset purchase agreement signed by the companies on January 30.
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.





